Phase 3 Recruiting Academic/Other
This Phase III Trial will determine whether adjuvant chemotherapy (ACT) added to ovarian function suppression (OFS) plus endocrine therapy (ET) is superior to OFS plus ET in improving invasive breast cancer-free survival (IBCFS) among prem…
Sponsor: NRG Oncology
NCT ID: NCT05879926
Sites in Oklahoma: - Cancer Centers of Southwest Oklahoma Research — Lawton, Oklahoma
- University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Phase 3 Recruiting Network
This trial has two cohorts of patients with human epidermal growth factor receptor (HER)-2-positive breast cancer that has spread to other places in the body. All patients must be receiving trastuzumab-based treatment. Both cohorts are bei…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03418961
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
- Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
- Oklahoma Cancer Specialists and Research Institute-Tulsa — Tulsa, Oklahoma
Phase 3 Recruiting Academic/Other
NRG-CC015 is a prospective, randomized phase III clinical trial to evaluate the efficacy of two distinct digital approaches for delivering a mindfulness-based intervention: a live, instructor-led version delivered over Zoom (MAPs LO), and …
Sponsor: NRG Oncology
NCT ID: NCT06748222
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 3 Recruiting Academic/Other
This phase III trial compares the effectiveness of fractionated stereotactic radiosurgery (FSRS) to usual care stereotactic radiosurgery (SRS) in treating patients with cancer that has spread from where it first started to the brain. Radia…
Sponsor: NRG Oncology
NCT ID: NCT06500455
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 3 Recruiting Industry
This is a Phase III open-label study to assess if camizestrant improves outcomes compared to standard adjuvant endocrine therapy for patients with ER+/HER2- early breast cancer with intermediate-high or high risk for disease recurrence who…
Sponsor: AstraZeneca
NCT ID: NCT05952557
Sites in Oklahoma: - Research Site — Oklahoma City, Oklahoma
Phase 2 Recruiting NIH
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical trials to study cancer treatment directed by genetic testing. Patients with solid tumors that have spread to nearby tissue or lymph nodes (locally adva…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT05564377
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This study will test the safety, including side effects, and determine the characteristics of a drug called Rina-S in participants with solid tumors. Participants will have solid tumor cancer that has spread through the body (metastatic) o…
Sponsor: Genmab
NCT ID: NCT05579366
Sites in Oklahoma: - University of Oklahoma - Health Sciences Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This is a dose-escalation and dose-expansion Phase 1/2a trial to evaluate the safety and tolerability of DB-1303/BNT323 in subjects with advanced solid tumors that express HER2.
Sponsor: DualityBio Inc.
NCT ID: NCT05150691
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 2 Recruiting Network
The purpose of this research study is to compare the effects (good and bad) on women and their cancer using proton radiation therapy. This study is being done to see if proton radiation therapy will prove to be beneficial for women with ea…
Sponsor: Proton Collaborative Group
NCT ID: NCT01766297
Sites in Oklahoma: - Oklahoma Proton Center — Oklahoma City, Oklahoma
Phase 1, Phase 2 Recruiting Industry
This interventional study will evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of ART6043 as monotherapy or in combination with olaparib.
Sponsor: Artios Pharma Ltd
NCT ID: NCT05898399
Sites in Oklahoma: - Stephenson Cancer Center - Oncology — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
TTX-080-001 is a Phase 1, open label, dose escalation and dose expansion clinical study to determine the safety, tolerability, and recommended Phase 2 dose of TTX-080 monotherapy (HLA-G inhibitor) and in combination with either pembrolizum…
Sponsor: Tizona Therapeutics, Inc
NCT ID: NCT04485013
Sites in Oklahoma: - University of Oklahoma — Oklahoma City, Oklahoma
Phase 1 Recruiting Industry
This is a first-in-human (FIH), multicenter, open-label Phase I study to investigate the safety, tolerability, preliminary antitumor activity, as well as pharmacokinetics (PK) and pharmacodynamics of XL309 (previously ISM3091) administered…
Sponsor: Exelixis
NCT ID: NCT05932862
Sites in Oklahoma: - Exelixis Clinical Site #13 — Oklahoma City, Oklahoma
Recruiting Academic/Other
This study collects blood and tissue samples from patients with cancer and without cancer to evaluate tests for early cancer detection. Collecting and storing samples of blood and tissue from patients with and without cancer to study in th…
Sponsor: Alliance for Clinical Trials in Oncology
NCT ID: NCT05334069
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
NA Recruiting Network
This randomized research trial studies how well serum tumor marker directed disease monitoring works in monitoring patients with hormone receptor positive Her2 negative breast cancer that has spread to other places in the body. Using marke…
Sponsor: SWOG Cancer Research Network
NCT ID: NCT03723928
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
Recruiting Academic/Other
This is a multi-site clinical study enrolling 2000 newly diagnosed patients with breast, colorectal, melanoma, non-Hodgkin lymphoma, or non-small cell lung cancer, who are planning to receive one or more systemic cancer directed therapies …
Sponsor: Wake Forest University Health Sciences
NCT ID: NCT06418204
Sites in Oklahoma: - Mercy Hospital Oklahoma City — Oklahoma City, Oklahoma
NA Recruiting NIH
The Vanguard Study is a feasibility study to explore several aspects of evaluating multi-cancer detection (MCD) tests in a future definitive randomized controlled trial. An MCD test measures markers in the blood in order to screen for mult…
Sponsor: National Cancer Institute (NCI)
NCT ID: NCT06995898
Sites in Oklahoma: - University of Oklahoma Health Sciences Center — Oklahoma City, Oklahoma
Recruiting Academic/Other
The purpose of this clinical trial is to evaluate radiation therapy (RT) completion rates among underrepresented cancer populations using qualitative measurements. Additionally, the study aims to assess the impact of patient navigators on …
Sponsor: University of Oklahoma
NCT ID: NCT07014618
Sites in Oklahoma: - OU Health Stephenson Cancer Center — Oklahoma City, Oklahoma